MedImmune lowers FluMist guidance
MedImmune reduces fourth quarter and full-year revenue guidance based on low demandfor its intranasal flu vaccine FluMist. Vaccine now expected to bring in $55 mil.-$85 mil. for 2003 instead of $120-$140 mil; total revenue expectations for the year reduced to $1.04 bil.-$1.1 bil. from $1.1 bil-$1.15 bil. MedImmune expects to record $10 mil. in FluMist "manufacturing supply goal payments and contractual reimbursements" in the fourth quarter and "manufacturing transfer payments and royalties" in the range of $7 mil-$37 mil. Wyeth has provisions in place for accepting FluMist returns (1"The Pink Sheet" Nov. 17, 2003, p. 35)...
You may also be interested in...
Wyeth and MedImmune plan to increase couponing for FluMist in the coming months
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.